301 related articles for article (PubMed ID: 15930352)
1. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R
Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
3. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
4. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
[TBL] [Abstract][Full Text] [Related]
5. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
[TBL] [Abstract][Full Text] [Related]
7. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD
Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868
[TBL] [Abstract][Full Text] [Related]
11. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
Hegmans JP; Veltman JD; Lambers ME; de Vries IJ; Figdor CG; Hendriks RW; Hoogsteden HC; Lambrecht BN; Aerts JG
Am J Respir Crit Care Med; 2010 Jun; 181(12):1383-90. PubMed ID: 20167848
[TBL] [Abstract][Full Text] [Related]
12. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
[TBL] [Abstract][Full Text] [Related]
13. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
[TBL] [Abstract][Full Text] [Related]
15. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
16. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
[TBL] [Abstract][Full Text] [Related]
17. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
Ovali E; Dikmen T; Sonmez M; Yilmaz M; Unal A; Dalbasti T; Kuzeyli K; Erturk M; Omay SB
J Exp Clin Cancer Res; 2007 Jun; 26(2):209-14. PubMed ID: 17725100
[TBL] [Abstract][Full Text] [Related]
18. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.
Bedrosian I; Mick R; Xu S; Nisenbaum H; Faries M; Zhang P; Cohen PA; Koski G; Czerniecki BJ
J Clin Oncol; 2003 Oct; 21(20):3826-35. PubMed ID: 14551301
[TBL] [Abstract][Full Text] [Related]
19. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
